IF we are expecting a large uptake of the product (indicated by $7M needed), then SP should rise AND as there is no floor price for the CR, then the dilution may not be that significant.
A big IF.
- Forums
- ASX - By Stock
- GMV
- Ann: Notice of Annual General Meeting
Ann: Notice of Annual General Meeting, page-56
-
- There are more pages in this discussion • 397 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online